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Innovation and Research in 




Significant advancements have been made in Cardiac surgery during the last 
decades, thanks to technological evolution. The enormous progress achieved has led 
to a relevant improvement in terms of surgical results, and at the same time, new 
ethical dilemmas have been addressed. Until the 90’s ethics in cardiac surgery mainly 
concerned significant moral problems caused by the introduction of extremely 
innovative techniques. However, today’s ethical issue focuses essentially on the 
doctor-patient relationship, other aspects of doctor’s practice concern relevant 
ethical perspectives. Ethics affects today the activity of the surgeon and the doctor 
in general. It is possible to distinguish clinical ethics, an ethics of health policies, and 
scientific research ethics. In the following chapter, we try to analyze the main ethical 
aspects concerning the application of cardiac surgical procedures.
Keywords: informed consent, LVAD (left ventricle assist device),  
destination therapy (DT), pandemic
1. Introduction (Informed consent)
In surgery, up to the 1960s, “paternalism” was an accepted and well-regarded 
tradition. The surgeon chose “the best” for his patient, who had a passive role in 
the choices regarding the treatment of his disease. On the other hand, in modern 
medicine, the patient collaborates with the surgeon to pursue the ultimate good, 
that is, health and recovery from illness [1].
For this reason, the act of informed consent does not represent a simple proof 
of the patient’s consent to treatment but describes the patient’s awareness of the 
pathology and the proposed therapies. Informed consent is not obtaining a signa-
ture on a piece of paper but a complex information process made up of different 
parts. Three main sets of elements characterize informed consent and are the 
initial conditions such as capacity and voluntariness; information, characterized by 
explanation and related recommendations; consent including decision and authori-
zation [2]. For preceding conditions, we mean the ability to understand information 
and to make decisions voluntarily. The lack of this capacity is not uncommon and 
often not recognized, although many tools are available to evaluate and measure 
it. Voluntariness is present when the patient’s choices are intentional and not 
conditioned by coercion or external influences. Surgeons should avoid putting 
pressure on patients by emphasizing benefits and minimizing risks. The information 
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elements include a detailed explanation of the nature of the disease and the treatment 
options. Risks, benefits, potential consequences of the recommended therapy, and 
possible alternatives must be elucidated. The likelihood of success, the prognosis 
without treatment are other aspects to explain. The elements relating to consent con-
clude the informed consent process. The decision made by the patient reflects which 
therapeutic option among those proposed to him he considers the best based on the 
information obtained. The consent is signed by both parties, like a real contract [3].
As proposed by the Italian Society of Cardiac Surgery, there are five informed 
consents that most commonly concern the cardiac surgeon’s activity:
1. Consent to coronary examination, coronary angioplasty, and interventional 
procedures (in collaboration with the cardiologist);
2. Consent to the processing of personal data for scientific purposes
3. Consent to cardiac surgery
4. Consent to transfusion of blood products
5. Consent of the patient’s family members (in particular situations)
Before signing the consent, the patient must make autonomous decisions, 
without external pressure (from the doctor, the family), understand the severity of 
the disease, and the risk/benefit ratio of the proposed interventions.
However, the surgeon remains a point of reference for the patient, who, however, 
informed and aware, entrusts his or her life in the hands of another person; for this 
reason, the surgeon must direct and advice based on their knowledge and scientific 
updating. This situation, for example, emerges in cardiac surgery when the patient, 
who is going to undergo a valve replacement, must choose between a biological and 
mechanical prosthesis. It is also possible that the surgeon finds himself in a condi-
tion of “paternalism, “which means he must make the decision “for the patient” 
who intends to leave him the choice of the valve prosthesis to be implanted. In this 
case, this must be reported in the written consent. Furthermore, the surgeon has 
to stratify the risk for each patient based on his experience and use the most recent 
risk calculators (EUROScore I and II - European System for Cardiac Operative Risk 
Evaluation, and STS score - to help him). Society of Thoracic Surgeons score) use-
ful for risk stratification and calculating the risk/benefit ratio [4].
2. Appropriateness of care
The theory of evaluative dynamism considers each therapeutic choice as 
proportionate/disproportionate; ordinary/extraordinary. The use of a means of 
life support is considered “proportionate” to the extent that it proves adequate to 
achieve a specific health goal. The proportionality of the therapeutic option is given 
by availability, technical possibility, and efficacy. Side effects and risks, possible 
therapeutic alternatives must be evaluated, and required technical and economic 
resources should be quantified. The extraordinary judgment correlates with a 
reasonably high probability of severe risks to the patient’s life and health concern-
ing his clinical condition and a low overall efficacy rate. When the effort to find the 
therapeutic option for life support is very high, or if the choice is linked to severe 
physical pain and the economic costs are too burdensome for the patient or his 
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relatives, a judgment of extraordinary nature and, therefore, sometimes of dispro-
portionality is configured [5]. In clinical practice, it is mandatory to use this ethical 
axiom: it is the duty of the doctor to use any proportionate and ordinary means for 
the treatment of the disease, the use of disproportionate and ordinary methods or 
proportionate but extraordinary measures may be optional; while it is not ethical to 
use means that are disproportionate and extraordinary at the same time.
3. Professional self regulation
Professional self-regulation is a personal or collective process of supervision that 
reflects the ethical concept of responsibility for patient care and includes account-
ability for that care’s scientific and clinical quality. The self-regulation process is 
best exemplified by introducing the clinical practice of critical reviews through 
routine meetings on mortality and morbidity [6].
4. Ethics in LVAD as DT
Left ventricular assist systems (LVAD) are widely used to treat patients with 
heart failure refractory to medical therapy as a bridge to heart transplantation [7]. 
In subjects who have severe comorbidities such as compromising their inclusion in 
the transplant list, LVADs can be used as definitive therapy (Destination Therapy -  
DT). This use implies a series of ethical aspects that include the correct selection 
of the patient, the patient’s precise information, and the definition of a possible 
protocol for deactivating the LVAD [8]. There are three ethical considerations 
regarding the selection of patients: the inclusion and exclusion criteria must be 
clearly explained, justified by rational diagnostic-therapeutic paths, and frequently 
discussed with the patient during the evaluation phase: The medical criteria must be 
supported by the most current medical, scientific evidence; The assessment must be 
conducted based on an explicit weighting of the costs, benefits, and risks associated 
with the procedure to be applied. The physician is responsible for providing clear 
information to the patient and family members, clarifying the risks and benefits of 
different treatment options, including medical treatment, palliative care, and VAD 
as destination therapy. The patient must be informed about the treatment’s goal as an 
innovative surgical procedure aimed at improving the quality of life. An advanced 
treatment plan must be presented to the patient, clarifying the patient’s preferences 
in case of complications. It is advisable to propose different scenarios that may occur 
during daily life through an interview with other subjects with LVAD.
Another ethical aspect concerns the possible interruption of therapy with 
mechanical support [9]. According to the principle of self-determination, the 
patient is fully entitled to stop medical treatment so that natural death can occur. 
A natural death can occur as a consequence of the deactivation of an LVAD due to 
a dysfunction of the device, due to coexisting comorbidities, or as a consequence 
of the progression of the disease. There are two ways of deactivating the LVAD. A 
team can help the patient disconnect the device from the power supply to cause a 
stop of the pump. The device’s interruption does not result in euthanasia since the 
ventricular function was already severely depressed before implanting the LVAD; 
the patient’s death occurs from the underlying heart disease. The second option 
involves surgical removal, but this alternative is somewhat complicated because it 
could cause the patient’s death and then. After all, it would contravene the goal of 
ensuring patient comfort [10].
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5. Innovation and research, conflict of interests
Scientific research is an essential part of a heart surgeon’s activity. Research 
must be understood as a systematic investigation aimed at a reflection, followed by 
scientific evaluation and analysis of the results. The scientific research results are the 
final product of the work and the correct analysis of the collected data. The faithful 
exposure of the latter is necessary to respond “ethically” to the need for health [11].
An ethical violation in the field of scientific research is present in case of falsi-
fication/fabrication of the results (failure to publish complications related to the 
intervention, operative mortality, causes of death during a clinical follow-up), or 
when it is present excessive influence of industry. In randomized clinical trials, in 
which patients are generally divided into two or more groups to receive a different 
treatment, absolute impartiality of judgment (not influenced by industry, personal 
interests) is required to analyze the results. For this reason, many of the studies are 
conducted in a “double-blind” manner, in which neither the doctor nor the patient 
is aware of the type of treatment received. Conflict of interest occurs when there 
are divergences between individual interests and the surgeon’s profession’s obliga-
tions [12]. Conflict of interest can arise due to problems related to the relation-
ship between surgeon and patient and between surgeon and industry, or finally, 
between public and private activities. Conflict of interest is frequent and even 
wholly unavoidable. Therefore, the moral purpose is not to cancel it altogether - it 
would be impossible - but to manage it, always managing to guarantee the preva-
lence of the primary interest (the patient’s health) over secondary interests (e.g., 
personal earnings and gratification, remuneration). The conflict of interest that 
may occur between surgeon and industry may be, for example, the choice of a 
prosthesis that does not give the same guarantees as other more tested prostheses 
(in this case, personal interest prevails).
6. Ethics in pandemic
In the event of a pandemic, the crucial role of the government, the community, 
and the health system is to intervene to isolate the disease and slow the spread of the 
infection. The health system should prepare for an epidemic peak by implementing 
care capabilities. If the epidemic peak exceeds the available resources necessary to 
cope with it, a careful resource allocation policy is indispensable. An appropriate 
resource allocation policy requires first identifying the decision-makers in charge of 
setting priorities in the distribution. Precise identification of the resources that are 
limited in time and require a distribution plan is essential. It is necessary to identify 
the subjects who can benefit most from the use of that particular resource. Finally, 
it is useful to determine if there is an ethical justification for giving certain groups a 
priority over others.
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